Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

  • Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx®  at Week 12  vs. placebo, with improvements as early as Week 11
     
  • ULTIMATE is the first ever Phase IIIb imaging study primarily looking at the time course of response to Cosentyx in biologic-naïve patients with active psoriatic arthritis (PsA) using Power Doppler ultrasonography (PDUS)1
     
  • PDUS is a sensitive technology, allowing detection and monitoring of early changes in synovitis and enthesitis1 …
/by